Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

William G. Wierda, John C. Byrd, Susan O'Brien, Steven Coutre, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Jan A. Burger, Don A. Stevens, Jeff Sharman, Paolo Ghia, Ian W. Flinn, Cathy Zhou, Joi Ninomoto, Danelle F. James, Constantine S. Tam

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - Jul 2019


  • chronic lymphocytic leukaemia
  • genomic risk factors
  • ibrutinib
  • tumour debulking
  • tumour lysis syndrome risk

ASJC Scopus subject areas

  • Hematology

Cite this